First‐line targeted therapy in combination with chemotherapy is the standard of care for most metastatic CRC patients with the type of targeted agent (e.g., anti‐EGFR, anti‐VEGF) depending on tumor location and molecular status (microsatellite instability, RAS, and BRAF status) [13]. The gene discussed is BRAF; the disease is neoplasm.